ANVS — Annovis Bio, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1477845 ·
Last close
$1.38
Market Cap
$58.80M
52W High
$5.50
52W Low
$1.04
ADV30
1,136,206
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -14,377,712 | -14,820,815 | 22,037,091 | 18,728,945 | 26,291,709 |
| Mar 2026 | 0 | — | -18,012,182 | -17,606,382 | 16,243,703 | 14,219,081 | 13,117,645 |
| Dec 2025 | 0 | — | -9,706,149 | -9,834,412 | 21,081,625 | 19,532,338 | 4,230,375 |
| Sep 2025 | 0 | — | -7,434,975 | -7,262,658 | 17,188,961 | 15,286,399 | 4,032,797 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,532,163
Investing CF
—
Financing CF
$18,515,069
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.64
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-181,310,041
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-41,424,759
Pretax Income TTM
$-40,923,510
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,695,258 | -28,854,197 | 21,081,625 | 4,230,375 | 16,851,250 | -25,619,703 |
| Dec 2024 | 0 | -26,694,928 | -24,590,375 | 13,925,633 | 4,617,987 | 9,307,646 | -21,894,604 |
| Dec 2023 | 0 | -45,035,011 | -56,204,313 | 10,208,264 | 17,959,110 | -7,750,846 | -39,967,304 |
| Dec 2022 | 0 | -25,511,279 | -25,328,567 | 36,022,069 | 7,698,539 | 28,323,530 | -17,312,934 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.86
Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $1.38 · call volume: 390 · put volume: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRRUF | IMMUTEP Ltd | $58.95M | $0.04 | — |
| MREO | Mereo BioPharma Group plc | $59.09M | $0.37 | — |
| BOLD | Boundless Bio, Inc. | $59.37M | $2.61 | — |
| ACET | Adicet Bio, Inc. | $59.45M | $6.35 | — |
| XLO | Xilio Therapeutics, Inc. | $59.55M | $9.05 | — |
News headlines (Yahoo Finance, 1h cache)
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-09-08 13:35 · Yahoo
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
2026-09-03 02:01 · Yahoo
Annovis to Host Corporate Update Webinar on September 2, 2026
2026-08-25 12:00 · Yahoo
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
2026-08-06 14:31 · Yahoo
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
2026-07-07 14:51 · Yahoo
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
2026-07-07 11:00 · Yahoo
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
2026-07-01 12:00 · Yahoo
Annovis Bio Regains NYSE Listing Compliance
2026-05-26 12:00 · Yahoo
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
2026-05-20 12:00 · Yahoo
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
2026-05-19 20:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.